CTI BioPharma Corp. and Baxter International’s Bioscience business today announced data from PERSIST-1 – a randomized Phase 3 registration-directed trial examining pacritinib for the treatment of myelofibrosis – in a late-breaking oral session at the 51st Annual Meeting of the American Society of Clinical Oncology, May 29-June 2, 2015 in Chicago, Ill.
Category: Research
Academic outrage as leading health journal editor sacked
Leading academics say they are shocked by the sudden removal of the editor of the Medical Journal of Australia, public health expert Professor Stephen Leeder.
Polio almost eradicated, experts aim to ‘finish the job’
The world is closer than ever to being able to wipe out polio, with zero cases of the crippling disease recorded across all of Africa this year and fewer than 25 globally, international experts say.
Biomarker analysis reveals several potential treatment targets in subtype of anal cancer
A multiplatform biomarker analysis of squamous cell anal carcinoma samples has revealed several actionable targets.
Pembrolizumab shows real promise against head and neck cancer, study suggests
Immunotherapy with the anti-PD-1 antibody pembrolizumab decreased the size of tumors by 30 percent or more in 24.8 percent of 132 patients with recurrent or metastatic head and neck cancer. That’s nearly twice as effective as the current preferred treatment.
Mental health research bolstered with new laser microscope technology
It’s hoped Newcastle’s new state-of-the-art laser microscope, the first of its kind in Australia, will lead to improved treatments for people suffering from mental health disorders.
Daratumumab achieves 29.2{c754d8f4a6af077a182a96e5a5e47e38ce50ff83c235579d09299c097124e52d} overall response rate in heavily pre-treated patients with multiple myeloma
Data from the international, multi-center, open-label, two-part, single-arm Phase 2 MMY2002 (SIRIUS) trial show treatment with single-agent daratumumab – an investigational, human anti-CD38 monoclonal antibody – achieved an overall response rate (ORR) of 29.2 percent (95{c754d8f4a6af077a182a96e5a5e47e38ce50ff83c235579d09299c097124e52d} CI, 20.8-38.9), as assessed by an independent review committee, in heavily pre-treated patients with multiple myeloma.
Rewriting the book on chemo-resistant cancers with a DNA library
Researcher are finding out why ovarian cancer is resistant to certain types of chemo and hope to eventually identify a different drug target.
Storing Blood Before Transfusion
Storing Blood Before TransfusionAmong patients undergoing complex cardiac surgeries, a clinical study found no advantage to only transfusing red blood cells stored for shorter periods of time.
Brain Mapping of Language Impairments
Brain Mapping of Language ImpairmentsResearchers mapped different language impairments to specific brain regions to reveal the basic organization of our language system.
Drugs Lessen Multiple Sclerosis Damage in Mice
Drugs Lessen Multiple Sclerosis Damage in MiceIn a mouse study, 2 drugs already on the market activated stem cells and repaired the type of brain damage seen in multiple sclerosis. The finding might lead to novel therapies.